#United States #Crohn's Disease #AbbVie #North Chicago #Risankizumab

AbbVie Seeks FDA Approval for Subcutaneous Risankizumab

AbbVie, a global biopharmaceutical leader, recently announced that it has submitted an application to the United States Food and Drug Administration (FDA) for the approval of subcutaneous Risankizumab as an induction therapy for adults suffering from moderately to severely active Crohn's disease. This significant step comes ahead of the company’s expectations for FDA approval to usher in a new treatment option for patients living with this challenging inflammatory bowel disease.

Understanding Crohn's Disease

Crohn's disease is a chronic inflammatory condition that can cause severe discomfort and emotional distress among patients. Affecting approximately 1 million people in the United States, the disease often has unpredictable symptoms that extend beyond just gastrointestinal distress. As a progressive illness, it can lead to painful complications and sometimes may require surgical intervention.

Kori Wallace, M.D., Ph.D., who is AbbVie’s Vice President and Global Head of Immunology Clinical Development, emphasized the need for advanced treatment options. He stated, “Patients with Crohn’s disease often carry a heavy burden that affects not only their physical health but also their mental well-being. Our aim is to enhance standard treatment and alleviate as much of this burden as possible.”

The AFFIRM Trial

The FDA application is based on promising results from the third-phase AFFIRM study (NCT06063967), which evaluated the efficacy and safety of subcutaneous induction therapy using Risankizumab in adults with moderate to severe Crohn's disease, regardless of their prior treatment history. It featured a randomized, placebo-controlled design and included a diverse population of 289 participants. Primary endpoints included achieving clinical remission at 12 weeks and demonstrating endoscopic improvement.

Risankizumab, which selectively inhibits interleukin-23 (IL-23), was initially approved by the FDA in 2022 as the first medication targeted specifically for this group of Crohn's disease patients. With the potential new subcutaneous formulation, patients might gain flexibility in choosing between injection and intravenous administration.

The Future of Treatment

AbbVie anticipates that if FDA approval is granted within this year, adults suffering from moderate to severe active Crohn's disease will benefit significantly. Patients would have the option to undergo subcutaneous induction therapy followed by maintenance therapy every eight weeks. This innovation marks a crucial stride in developing more patient-friendly therapeutic approaches.

Conclusion

With the ongoing commitment to addressing the complex needs of patients with Crohn's disease, AbbVie continues to invest in research and innovative solutions. The submission of this application represents a noteworthy progression toward improving the quality of life for individuals affected by this chronic condition. By advancing treatment options, AbbVie is striving to ensure that every patient can achieve a life free from the burdens of Crohn's disease.

Additional Information

Those interested in learning more about Risankizumab and AbbVie's approach to healthcare can visit AbbVie’s website or check out their social media channels for updates. The journey toward innovation in the field of immunology is ongoing, as AbbVie remains dedicated to enhancing lives through science and medicine.